|
WO1991000916A2
(en)
|
1989-07-06 |
1991-01-24 |
The Regents Of The University Of California |
Receptors for fibroblast growth factors
|
|
DK0646182T3
(da)
|
1992-06-18 |
1996-09-16 |
Whittier Inst Diabetes & Endoc |
Fremgangsmåde til påvisning af neoplastiske sygdomme
|
|
AU6446194A
(en)
|
1993-03-17 |
1994-10-11 |
Whittier Institute For Diabetes And Endocrinology, The |
Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
|
|
US6517872B1
(en)
|
1995-06-12 |
2003-02-11 |
Yeda Research And Development Co., Ltd. |
FGFR3 as a marker for mesenchymal skeletal progenitor cells
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
US20030143676A1
(en)
|
1999-03-25 |
2003-07-31 |
Genesis Research And Development Corporation Limited |
Fibroblast growth factor receptors and methods for their use
|
|
EP1208231B2
(en)
|
1999-05-05 |
2009-12-30 |
Institut Curie |
Means for detecting and treating pathologies linked to fgfr3
|
|
US7135311B1
(en)
|
1999-05-05 |
2006-11-14 |
Institut Curie |
Means for detecting and treating pathologies linked to FGFR3
|
|
AU7764200A
(en)
|
1999-10-06 |
2001-05-10 |
Tigenix N.V. |
In vivo assay and molecular markers for testing the phenotypic stability of cellpopulations, and selecting cell populations for autologous transplantation
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
ES2363765T3
(es)
|
2002-01-31 |
2011-08-16 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonistas de fgfr.
|
|
NZ537208A
(en)
|
2002-06-27 |
2009-02-28 |
Adipogen Pharmaceuticals Pty Ltd |
Differentiation modulating agents and uses therefor
|
|
AU2003265057A1
(en)
|
2002-09-04 |
2004-03-29 |
Abtech |
Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
|
|
CA2510715A1
(en)
|
2002-12-20 |
2004-07-08 |
Enkam Pharmaceuticals A/S |
Method of modulation of interaction between receptor and ligand
|
|
WO2004074506A2
(en)
|
2003-02-13 |
2004-09-02 |
Mergen Ltd |
Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
|
|
US8124331B2
(en)
|
2003-03-26 |
2012-02-28 |
Progenika Biopharma, S.A. |
In vitro method to detect bladder transitional cell carcinoma
|
|
IL156495A0
(en)
|
2003-06-17 |
2004-01-04 |
Prochon Biotech Ltd |
Use of fgfr3 antagonists for treating t cell mediated diseases
|
|
WO2005066211A2
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
EP1544213B1
(en)
|
2003-12-19 |
2008-02-20 |
Charité - Universitätsmedizin Berlin |
Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
|
|
AU2005216547B2
(en)
|
2004-02-24 |
2009-03-12 |
Allergan, Inc. |
Botulinum toxin screening assays
|
|
EP1773305A2
(en)
|
2004-05-25 |
2007-04-18 |
Yale University Corporation |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
AU2005302083A1
(en)
|
2004-11-04 |
2006-05-11 |
Fibron Limited |
Treatment of B-cell malignancies
|
|
EP1659175A1
(en)
|
2004-11-18 |
2006-05-24 |
Institut Curie |
Alterations in seborrheic keratoses and their applications
|
|
ATE423140T1
(de)
|
2005-01-05 |
2009-03-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
EP1861419B1
(en)
|
2005-03-15 |
2011-06-29 |
Allergan, Inc. |
Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
|
|
NZ565511A
(en)
|
2005-07-22 |
2011-03-31 |
Five Prime Therapeutics Inc |
Compositions and methods of treating disease with FGFR fusion proteins
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
JP2009511613A
(ja)
|
2005-10-17 |
2009-03-19 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
神経細胞接着分子l1のペプチド断片を含む新規fgf受容体結合化合物
|
|
WO2007067968A2
(en)
|
2005-12-08 |
2007-06-14 |
Novartis Ag |
Effects of inhibitors of fgfr3 on gene transcription
|
|
US8101721B2
(en)
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
WO2008127707A1
(en)
|
2007-04-13 |
2008-10-23 |
Dana Farber Cancer Institute, Inc. |
Receptor tyrosine kinase profiling
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
ES2553390T3
(es)
|
2008-02-25 |
2015-12-09 |
Nestec S.A. |
Método para la detección de receptores truncados intracelulares
|
|
WO2009146033A2
(en)
|
2008-03-31 |
2009-12-03 |
Sma Foundation |
Compositions and methods for modulating smn activity
|
|
KR101590495B1
(ko)
|
2008-05-29 |
2016-02-01 |
갤럭시 바이오테크, 엘엘씨 |
염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
|
|
WO2010002862A2
(en)
|
2008-07-01 |
2010-01-07 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (fgfr3) binding proteins
|
|
AR073770A1
(es)
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
ES2549769T3
(es)
|
2009-03-25 |
2015-11-02 |
Genentech, Inc. |
Anticuerpos anti-FGFR3 y métodos que emplean los mismos
|
|
WO2011088196A2
(en)
|
2010-01-14 |
2011-07-21 |
Yale University |
Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
|
|
CN105859889B
(zh)
*
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
US8790651B2
(en)
*
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
WO2013088191A1
(en)
|
2011-12-12 |
2013-06-20 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
|
|
KR20220017512A
(ko)
|
2012-03-08 |
2022-02-11 |
아스테라스 세이야쿠 가부시키가이샤 |
신규 fgfr3 융합체
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US20150292030A1
(en)
|
2012-11-27 |
2015-10-15 |
Board Of Regents, The University Of Texas System |
Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
|
|
CN105209607B
(zh)
|
2013-04-05 |
2020-02-07 |
大学健康网络 |
产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物
|
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
|
|
SG11201706727XA
(en)
|
2015-02-19 |
2017-09-28 |
Bioclin Therapeutics Inc |
Methods, compositions, and kits for treatment of cancer
|
|
CN110785184A
(zh)
|
2017-02-06 |
2020-02-11 |
雷尼尔医疗公司 |
用于治疗癌症的方法,组合物和试剂盒
|